Literature DB >> 20056123

Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.

Changyou Zhan1, Bing Gu, Cao Xie, Jin Li, Yu Liu, Weiyue Lu.   

Abstract

The use of glioblastoma-targeted drug delivery system facilitates efficient delivery of chemotherapeutic agents to malignant gliomas in the central nervous system while minimizing high systemic doses associated with debilitating toxicities. To employ the high binding affinity of a cyclic RGD peptide (c(RGDyK), cyclic Arginine-Glycine-Aspartic acid-D-Tyrosine-Lysine) with integrin alpha(v)beta(3) over-expressed on tumor neovasculature and U87MG glioblastoma cells, we prepared paclitaxel-loaded c(RGDyK)-Poly(ethylene glycol)-block-poly(lactic acid) micelle (c(RGDyK)-PEG-PLA-PTX). In vitro physicochemical characterization of these novel micelles showed satisfactory encapsulated efficiency, loading capacity and size distribution. In vitro cytotoxicity studies proved that the presence of c(RGDyK) enhanced the anti-glioblastoma cell cytotoxic efficacy by 2.5 folds. The binding affinity of c(RGDyK)-PEG-PLA micelle with U87MG cells was also investigated. The competitive binding IC(50) value of c(RGDyK)-PEG-PLA micelle was 26.30 nM, even lower than that of c(RGDyK) (56.23 nM). In U87MG glioblastoma-bearing nude mice model, biodistribution of (125)I-radiolabeled c(RGDyK)-PEG-PLA or DiR encapsulated micelles and anti-glioblastoma pharmacological effect was investigated after intravenous administration. c(RGDyK)-PEG-PLA micelle accumulated in the subcutaneous and intracranial tumor tissue, and when loaded with PTX (c(RGDyK)-PEG-PLA-PTX), exhibited the strongest tumor growth inhibition among the studied paclitaxel formulations. The anti-glioblastoma effect of c(RGDyK)-PEG-PLA-PTX micelle was also reflected in the median survival time of mice bearing intracranial U87MG tumor xenografts where the median survival time of c(RGDyK)-PEG-PLA-PTX micelle-treated mice (48 days) was significantly longer than that of mice treated with PEG-PLA-PTX micelle (41.5 days), Taxol (38.5 days) or saline (34 days). Therefore, our results suggested that c(RGDyK)-PEG-PLA micelle may be a potential drug delivery system in the treatment of integrin alpha(v)beta(3) over-expressed glioblastoma. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20056123     DOI: 10.1016/j.jconrel.2009.12.020

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  61 in total

1.  Block copolymer micelles with acid-labile ortho ester side-chains: Synthesis, characterization, and enhanced drug delivery to human glioma cells.

Authors:  Rupei Tang; Weihang Ji; David Panus; R Noelle Palumbo; Chun Wang
Journal:  J Control Release       Date:  2010-12-29       Impact factor: 9.776

2.  A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.

Authors:  Xishan Chen; Lingyu Tai; Jie Gao; Jianchang Qian; Mingfei Zhang; Beibei Li; Cao Xie; Linwei Lu; Wuyuan Lu; Weiyue Lu
Journal:  J Control Release       Date:  2015-09-30       Impact factor: 9.776

3.  The novel agent phospho-glycerol-ibuprofen-amide (MDC-330) inhibits glioblastoma growth in mice: an effect mediated by cyclin D1.

Authors:  Lauren E Bartels; George Mattheolabakis; Brandon M Vaeth; Joseph F LaComb; Ruixue Wang; Jizu Zhi; Despina Komninou; Basil Rigas; Gerardo G Mackenzie
Journal:  Carcinogenesis       Date:  2016-02-10       Impact factor: 4.944

4.  Luteolin nanoparticle in chemoprevention: in vitro and in vivo anticancer activity.

Authors:  Debatosh Majumdar; Kyung-Ho Jung; Hongzheng Zhang; Sreenivas Nannapaneni; Xu Wang; A R M Ruhul Amin; Zhengjia Chen; Zhuo G Chen; Dong M Shin
Journal:  Cancer Prev Res (Phila)       Date:  2014-01

5.  Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(DL-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine.

Authors:  Elham A Mohamed; Yunqi Zhao; Mahasen M Meshali; Connie M Remsberg; Thanaa M Borg; Abdel Monem M Foda; Jody K Takemoto; Casey L Sayre; Stephanie E Martinez; Neal M Davies; M Laird Forrest
Journal:  J Pharm Sci       Date:  2012-07-17       Impact factor: 3.534

6.  Interfacial activity assisted surface functionalization: a novel approach to incorporate maleimide functional groups and cRGD peptide on polymeric nanoparticles for targeted drug delivery.

Authors:  Udaya S Toti; Bharath Raja Guru; Alex E Grill; Jayanth Panyam
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

7.  RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells.

Authors:  Dan Shan; Jason Li; Ping Cai; Preethy Prasad; Franky Liu; Andrew Michael Rauth; Xiao Yu Wu
Journal:  Drug Deliv Transl Res       Date:  2015-02       Impact factor: 4.617

8.  Preparation and characterization of galactosylated glycol chitosan micelles and its potential use for hepatoma-targeting delivery of doxorubicin.

Authors:  Jing-Mou Yu; Wei-Dong Li; Lu Lu; Xue-Yun Zhou; Dian-Yuan Wang; Hui-Min Li; Xiao-Yuan Xu; Jian Chen
Journal:  J Mater Sci Mater Med       Date:  2013-12-14       Impact factor: 3.896

9.  Fatty acid-RGD peptide amphiphile micelles as potential paclitaxel delivery carriers to α(v)β₃ integrin overexpressing tumors.

Authors:  Narashima Murthy Javali; April Raj; Poonam Saraf; Xiaoling Li; Bhaskara Jasti
Journal:  Pharm Res       Date:  2012-07-24       Impact factor: 4.200

10.  The use of borneol as an enhancer for targeting aprotinin-conjugated PEG-PLGA nanoparticles to the brain.

Authors:  Lin Zhang; Limei Han; Jing Qin; Weiyue Lu; Jianxin Wang
Journal:  Pharm Res       Date:  2013-04-25       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.